ALK and lung carcinoma: We then questioned whether lorlatinib used at concentrations efficacious against ALK-rearranged lung cancer cells but non-toxic to ALK-negative cells could promote substantial lipidome changes in Huh-7 cells (Figure 1B; Table 1).